These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 35605554)
1. Generation of wild-type rat Glucocerebrosidase homology modeling: Identification of putative interactions site and mechanism for chaperone using combined in-silico and in-vitro studies. Tripathi P; Ganeshpurkar A; Singh SK; Krishnamurthy S Bioorg Chem; 2022 Sep; 126():105871. PubMed ID: 35605554 [TBL] [Abstract][Full Text] [Related]
2. Identification of novel glucocerebrosidase chaperone for potential treatment of Parkinson's disease: An approach using in silico virtual screening, molecular docking and molecular dynamics, and in vitro studies. Tripathi P; Ganeshpurkar A; Singh SK; Krishnamurthy S Int J Biol Macromol; 2023 Feb; 228():453-466. PubMed ID: 36565835 [TBL] [Abstract][Full Text] [Related]
8. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. Mullin S; Smith L; Lee K; D'Souza G; Woodgate P; Elflein J; Hällqvist J; Toffoli M; Streeter A; Hosking J; Heywood WE; Khengar R; Campbell P; Hehir J; Cable S; Mills K; Zetterberg H; Limousin P; Libri V; Foltynie T; Schapira AHV JAMA Neurol; 2020 Apr; 77(4):427-434. PubMed ID: 31930374 [TBL] [Abstract][Full Text] [Related]
9. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639 [TBL] [Abstract][Full Text] [Related]
10. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Migdalska-Richards A; Daly L; Bezard E; Schapira AH Ann Neurol; 2016 Nov; 80(5):766-775. PubMed ID: 27859541 [TBL] [Abstract][Full Text] [Related]
11. A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. Yang SY; Beavan M; Chau KY; Taanman JW; Schapira AHV Stem Cell Reports; 2017 Mar; 8(3):728-742. PubMed ID: 28216145 [TBL] [Abstract][Full Text] [Related]
12. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Bendikov-Bar I; Maor G; Filocamo M; Horowitz M Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495 [TBL] [Abstract][Full Text] [Related]
13. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. Silveira CRA; MacKinley J; Coleman K; Li Z; Finger E; Bartha R; Morrow SA; Wells J; Borrie M; Tirona RG; Rupar CA; Zou G; Hegele RA; Mahuran D; MacDonald P; Jenkins ME; Jog M; Pasternak SH BMC Neurol; 2019 Feb; 19(1):20. PubMed ID: 30738426 [TBL] [Abstract][Full Text] [Related]
14. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease. Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084 [TBL] [Abstract][Full Text] [Related]
15. Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease. Mishra A; Krishnamurthy S Naunyn Schmiedebergs Arch Pharmacol; 2020 Mar; 393(3):429-444. PubMed ID: 31654086 [TBL] [Abstract][Full Text] [Related]
16. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic Insight into the Mode of Action of Acid β-Glucosidase Enhancer Ambroxol. Pantoom S; Hules L; Schöll C; Petrosyan A; Monticelli M; Pospech J; Cubellis MV; Hermann A; Lukas J Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408914 [TBL] [Abstract][Full Text] [Related]
18. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808 [TBL] [Abstract][Full Text] [Related]
19. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Migdalska-Richards A; Ko WKD; Li Q; Bezard E; Schapira AHV Synapse; 2017 Jul; 71(7):. PubMed ID: 28295625 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacological chaperone therapy for the treatment of inborn errors of metabolism]. Lipiński P; Jezela-Stanek A; Tylki-Szymańska A Postepy Biochem; 2022 Sep; 68(3):255-263. PubMed ID: 36317990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]